SCHEMBL4359669

SCHEMBL4359669

O=C1N=C(N2CCOCC2)SC1=CC(Cl)=Cc1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.76
ALDH1A1 P00352 7/20 0.76
RAB9A P51151 5/20 0.76
NPC1 O15118 3/20 0.76
SMN1; SMN2 Q16637 3/20 0.76
HCRTR1 O43613 1/20 0.76
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
CYP1A2 P05177 2/20 0.64
CYP2C19 P33261 2/20 0.64
GAA P10253 2/20 0.52
KDM4E B2RXH2 1/20 0.52
POLB P06746 2/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50
DCTPP1 Q9H773 1/20 0.49
HPGD P15428 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
SENP1 Q9P0U3 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4364702 0.87 MAPT (0.58) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4357147 0.85 MAPT (0.74) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4354202 0.83 MAPT (0.53) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4354258 0.82 ALDH1A1 (0.78) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4354253 0.82 ALDH1A1 (0.78) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
Bromide SCHEMBL4352446 0.81 ALDH1A1 (0.76) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
Bromide SCHEMBL4352442 0.81 ALDH1A1 (0.76) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4353893 0.80 MAPT (0.51) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4363209 0.78 MAPT (1.00) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
Bromide SCHEMBL4362322 0.77 MAPT (0.98) MAPTALDH1A1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs GRUENENTHAL GMBH (DE) 2009-08-27 US disclosed
EP-1890695-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2008-02-27 EP disclosed
WO-2006122777-A2 USE OF 2,5-DISUBSTITUTED THIAZOL-4-ONE DERIVATIVES IN DRUGS Grünenthal GmbH (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215758-A1 Use of 2,5-Disubstituted Thiazol-4-One Derivatives in Drugs ABCB1, ABCG2, SLC5A2 MAPT 1470/4885ALDH1A1 284/4885RAB9A 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.